Security Snapshot

Beta Bionics, Inc. - Common Stock, $0.0001 par value per share (BBNX) Institutional Ownership

CUSIP: 08659B102

13F Institutional Holders and Ownership History from Q1 2025 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

128

Shares (Excl. Options)

49,288,407

Price

$10.02

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+2,286,070
Value change
-$73,044,020
Number of holders
128
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
44,369,313
SEC-reported price per share
$15.67
Insider filing price
$15.67
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • BBNX - Beta Bionics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 08659B102.
  • 128 institutions reported positions in Q1 2026.
  • 11 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 128 to 6 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $493,788,078 to $1,531,335.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 128 institutions filings for Q1 2026.

Open SEC evidence

Security key

08659B102

Latest holder period

Q1 2026

13F holders

128

13D/G owners

11

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
11
Security
BBNX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
EVENTIDE ASSET MANAGEMENT, LLC 13% +19% $52,677,024 +$9,643,640 5,945,488 +22% Eventide Asset Management, LLC 31 Mar 2026
Soleus Capital Group, LLC 9.8% $38,580,879 4,354,501 Levy Guy 31 Mar 2026
Zone Healthcare Holdings, LLC 9.9% +25% $85,717,590 +$17,618,729 4,313,920 +26% Dapice Joshua J. 30 Sep 2025
MORGAN STANLEY 8.6% +26% $74,305,196 +$16,109,185 3,739,567 +28% Morgan Stanley 30 Sep 2025
Farallon Capital Partners, L.P. 8.1% -18% $31,966,171 -$6,839,920 3,607,920 -18% Dapice Joshua J. 31 Mar 2026
Sands Capital Life Sciences Pulse Fund II, L.P. 8.2% +13% $48,410,732 +$5,636,946 3,570,113 +13% Sands Capital Life Sciences Pulse Fund II. L.P. 30 Jun 2025
BlackRock, Inc. 6.4% $55,215,708 2,778,764 BlackRock, Inc. 30 Sep 2025
Point72 Asset Management, L.P. 5.2% $34,190,043 2,290,023 Point72 Asset Management, L.P. 18 Feb 2026
RTW INVESTMENTS, LP 4.5% -20% $17,720,000 -$4,430,000 2,000,000 -20% RTW Investments, LP 31 Mar 2026
PERCEPTIVE ADVISORS LLC 3.7% $21,609,324 1,593,608 Perceptive Advisors LLC 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 1.8% -70% $15,835,993 -$29,602,207 796,964 -65% Millennium Management LLC 30 Sep 2025

As of 31 Mar 2026, 128 institutional investors reported holding 49,288,407 shares of Beta Bionics, Inc. - Common Stock, $0.0001 par value per share (BBNX). This represents 111% of the company’s total 44,369,313 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
101%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
EVENTIDE ASSET MANAGEMENT, LLC 13% 5,945,488 +19% 0.99% $59,567,287
Soleus Capital Management, L.P. 9.8% 4,354,501 +72% 1.8% $43,632,100
MORGAN STANLEY 9.5% 4,227,634 +22% 0% $42,360,893
Sands Capital Alternatives, LLC 8.4% 3,708,043 +3.9% 8.8% $37,154,591
FARALLON CAPITAL MANAGEMENT LLC 8.1% 3,607,920 -16% 0.24% $36,151,358
BlackRock, Inc. 6.8% 3,038,595 +4.3% 0% $30,446,722
Point72 Asset Management, L.P. 5.7% 2,525,040 +156% 0.04% $25,300,901
Vestal Point Capital, LP 5% 2,211,518 +269% 0.62% $22,159,410
RTW INVESTMENTS, LP 4.5% 2,000,000 -20% 0.2% $20,040,000
VANGUARD CAPITAL MANAGEMENT LLC 3.9% 1,727,977 0% 0% $17,314,330
Eversept Partners, LP 3.2% 1,414,838 +109% 0.93% $14,176,677
DEERFIELD MANAGEMENT COMPANY, L.P. 3% 1,324,000 +41% 0.16% $13,266,480
Omega Fund Management, LLC 3% 1,316,183 0% 8.1% $13,188,154
STATE STREET CORP 2.1% 946,087 +9.6% 0% $9,479,792
GEODE CAPITAL MANAGEMENT, LLC 2.1% 932,678 +1.2% 0% $9,347,808
MILLENNIUM MANAGEMENT LLC 1.9% 860,866 -8.9% 0.01% $8,625,877
PERCEPTIVE ADVISORS LLC 1.9% 842,944 +40% 0.17% $8,446,299
UBS Group AG 1.4% 623,253 +148% 0% $6,244,995
Balyasny Asset Management L.P. 1.4% 617,915 +627% 0.01% $6,191,508
Bruce & Co., Inc. 1.2% 550,700 1.6% $5,518,014
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 1.2% 546,132 -59% 0.01% $5,472,243
Y-Intercept (Hong Kong) Ltd 1.1% 485,854 +4237% 0.09% $4,868,257
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.73% 322,467 -2.8% 0% $3,231,119
JPMORGAN CHASE & CO 0.69% 307,229 -12% 0% $3,029,279
NORTHERN TRUST CORP 0.67% 295,818 +4% 0% $2,964,096

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
6
Latest
Q1 2026
Rows shown
1-6 of 6
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 116,350 $1,531,335 -$6,631,706 $15.67 6
2026 Q1 49,288,407 $493,788,078 -$73,044,020 $10.02 128
2025 Q4 47,221,349 $1,439,223,888 +$22,363,225 $30.47 159
2025 Q3 48,310,134 $959,915,542 +$85,339,869 $19.87 127
2025 Q2 44,848,348 $652,883,600 +$53,846,940 $14.56 114
2025 Q1 41,702,710 $507,967,865 +$504,374,335 $12.24 102
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .